Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.

The detailed kinetic model of Prostaglandin H Synthase-1 (COX-1) was developed to in silico test and predict inhibition effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on target. The model takes into account key features of the complex catalytic mechanism of cyclooxygenase-1, converting arachidonic acid to prostaglandin PGH(2), and includes the description of the enzyme interaction with various types of NSAIDs (reversible/irreversible, non-selective and selective to COX-1/COX-2). Two different versions of the model were designed to simulate the inhibition of COX-1 by NSAIDs in two most popular experimental settings - in vitro studies with purified enzyme, and the experiments with platelets. The developed models were applied to calculate the dose-dependence of aspirin and celecoxib action on COX- 1 in vitro and in vivo conditions. The mechanism of the enhancement of aspirin efficiency in platelet as compared to its action on purified COX-1 was elucidated. The dose-dependence of celecoxib simulated with the use of the "in vivo" version of the model predicted potentially strong inhibitory effect of celecoxib on thromboxan production in platelets. Simulation of the combined effect of two NSAIDs, aspirin and celecoxib, on COX-1 allowed us to reveal the mechanism underlying the suppression of aspirin-mediated COX-1 inhibition by celecoxib. We discuss our modelling results in the context of the on-going debates on the potential cardio-vascular risks associated with co-administration of various types of NSAIDs.

[1]  A. Brash.  Arachidonic acid as a bioactive molecule. , 2001, The Journal of clinical investigation.

[2]  H. V. Van Wart,et al.  Comparison of the Peroxidase Reaction Kinetics of Prostaglandin H Synthase-1 and -2* , 1999, The Journal of Biological Chemistry.

[3]  W. Lands,et al.  Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. , 1994, Journal of Biological Chemistry.

[4]  A. Tsai,et al.  Cyclooxygenase inactivation kinetics during reaction of prostaglandin H synthase-1 with peroxide. , 2003, Biochemistry.

[5]  J. Pepper,et al.  Stronger inhibition by nonsteroid anti‐inflammatory drugs of cyclooxygenase‐1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Wei,et al.  Comparison of branched-chain and tightly coupled reaction mechanisms for prostaglandin H synthase. , 1995, Biochemistry.

[7]  William L. Smith,et al.  The 19-amino Acid Cassette of Cyclooxygenase-2 Mediates Entry of the Protein into the Endoplasmic Reticulum-associated Degradation System* , 2006, Journal of Biological Chemistry.

[8]  D. Swinney,et al.  The Kinetic Factors That Determine the Affinity and Selectivity for Slow Binding Inhibition of Human Prostaglandin H Synthase 1 and 2 by Indomethacin and Flurbiprofen (*) , 1996, The Journal of Biological Chemistry.

[9]  L. Rome,et al.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Gierse,et al.  Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.

[11]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. A. van der Donk,et al.  Comparison of the properties of prostaglandin H synthase-1 and -2. , 2003, Progress in lipid research.

[13]  R. de Caterina,et al.  Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease , 2006, Clinical pharmacology and therapeutics.

[14]  M. Dougados,et al.  Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. , 1999, Rheumatology.

[15]  R. Kulmacz.  Topography of prostaglandin H synthase. Antiinflammatory agents and the protease-sensitive arginine 253 region. , 1989, The Journal of biological chemistry.

[16]  P. Delafontaine,et al.  Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. , 2004, Journal of the American College of Cardiology.

[17]  B. Stec,et al.  Role of Asn-382 and Thr-383 in Activation and Inactivation of Human Prostaglandin H Synthase Cyclooxygenase Catalysis* , 2004, Journal of Biological Chemistry.

[18]  Igor Goryanin,et al.  Mathematical simulation and analysis of cellular metabolism and regulation , 1999, Bioinform..

[19]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[20]  R. Kulmacz,et al.  Hydroperoxide Dependence and Cooperative Cyclooxygenase Kinetics in Prostaglandin H Synthase-1 and -2* , 1999, The Journal of Biological Chemistry.

[21]  Jilly F. Evans,et al.  Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. , 1996, Biochemical pharmacology.

[22]  H. Krumholz,et al.  The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype? , 2004, Journal of the American College of Cardiology.

[23]  M. Percival,et al.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H Perrier,et al.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  P. Majerus,et al.  Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Ruf,et al.  Higher oxidation states of prostaglandin H synthase. EPR study of a transient tyrosyl radical in the enzyme during the peroxidase reaction. , 1988, European journal of biochemistry.

[28]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.